Field Brief: TCCC 2026 — Tourniquet Conversion, OTFC Out, and the Pediatric Guidelines We Should've Had a Decade Ago
- John Gomez
- 6 days ago
- 10 min read
The Committee on Tactical Combat Casualty Care published its most consequential rewrite in years on 1 May 2026. Tourniquet reposition and conversion are now expected at the All-Service-Member and Combat Lifesaver tiers. OTFC and IV fentanyl are out of first-line analgesia. Suzetrigine is in. And, for the first time in the program's history, pediatrics has its own document. Here is what working tac medics — military and civilian — actually need to know.
It is hour one fifty-five since the high-and-tight went on a young Marine's femoral. The aircraft is forty minutes out. The patient is awake, pissed off, and asking for water. You — the tactical paramedic in the back of the truck — are now looking at a clinical decision that did not exist in this form before May 1st of this year: do you reposition that tourniquet, convert it to a pressure-and-hemostatic combination, or leave it alone until somebody with more letters after their name takes the call?
Under the 2024 TCCC guideline, the answer was structured around tier-of-care. A Combat Medic or Corpsman could consider conversion under defined conditions; the casualty's buddy with the CLS card could not. Under the guideline CoTCCC published on 1 May 2026, that line moves. The Combat Lifesaver and the All-Service-Member tier are now expected to perform tourniquet reposition and tourniquet conversion under defined conditions. That sounds like a small edit. It is not. It is the most consequential rewrite of the “apply and forget” protocol since the Iraq War casualty data forced the modern tourniquet renaissance in the first place.
This Field Brief covers the May 2026 TCCC update — what changed, what it means for working tac medics on both sides of the military-civilian divide, and where civilian TECC is going to land when it inevitably borrows from this document.
What CoTCCC published on 1 May 2026
The Committee on Tactical Combat Casualty Care released the current TCCC Guidelines on 1 May 2026, available through the Joint Trauma System and mirrored on the Allogy library. The committee identified two explicit focus areas: airway management in Tactical Field Care, and traumatic brain injury management in Tactical Field Care.
The substantive changes are concentrated in six places:
Tourniquet reposition and tourniquet conversion expanded to the All-Service-Member and Combat Lifesaver tiers.
Analgesia rewritten: oral transmucosal fentanyl citrate (OTFC) and IV fentanyl are removed from initial pain management and replaced by a suzetrigine-anchored Combat Wound Medication Pack plus a simplified ketamine regimen.
Antibiotic regimen replaced: cefadroxil 1 g PO (preferred) or cephalexin 500 mg PO (alternative) substitute for moxifloxacin; ceftriaxone 2 g IV/IO push over 3–5 minutes replaces ertapenem for the parenteral option.
TBI management in TFC tightened, with continuous EtCO2 now required in addition to SpO2 to assess ventilation, not just oxygenation.
A focused refinement on penetrating eye trauma management.
For the first time in the program's history, a standalone pediatric TCCC document.
Two of those changes alone — the tourniquet conversion scope shift and the analgesia overhaul — would warrant a Field Brief on their own. Together they reset the standard.
Tourniquet Conversion is Now an All-Service-Member Task
The evidence supporting this shift has been building for a decade and got loud in 2025. A retrospective study published in the European Journal of Trauma and Emergency Surgery analyzed eleven years of prehospital tourniquet applications presenting to a Level 1 trauma center: 88 applications across 86 patients. Seventy-seven percent of those applications were judged non-indicated. The proportion of non-indicated applications increased over the study period (p = 0.03). At least one potentially tourniquet-attributable complication was identified in thirty-eight percent of patients.
JSOM published Proposed Change 25-2 — the working paper behind the 2026 conversion language — in late 2025, building on Russo-Ukrainian War casualty data documenting unnecessary application, ischemic complications from prolonged use, and dangerous conversion delays during evacuation. The 2026 guideline turns that proposal into doctrine.
What the new language actually says, in plain terms:
The All-Service-Member and Combat Lifesaver tiers are expected to perform tourniquet reposition (moving a high-and-tight tourniquet to two to three inches above the wound) and tourniquet conversion (replacing the tourniquet with a hemostatic or pressure dressing) under defined conditions.
Conversion should be considered before two hours from application when feasible.
The window from two to six hours requires monitoring for reperfusion syndrome. This is the band where conversion is most dangerous and also most necessary.
Beyond six hours, conversion is generally not recommended without higher-level care available.
The standing exclusions still apply: do not convert in a patient who is or has been in shock, do not convert when the wound cannot be monitored for re-bleeding, do not convert if the limb is non-viable or the casualty is undergoing amputation.
The doctrinal logic is the same logic that runs through every modern resuscitation guideline. The first ten minutes get the patient alive. The next two hours decide what shape they are in when surgery starts. Treating tourniquet application as a closed loop — apply, label time, walk away — was always a placeholder for the absence of a conversion infrastructure. The 2026 update finally says so out loud.
The controversy is implementation. ASM and CLS-tier training infrastructure in most US units is built around application, not conversion. Civilian Tactical Emergency Casualty Care (TECC) language has historically been even more conservative: in most agencies, conversion is a paramedic-and-above skill, often pinned to a medical-director-specific protocol. Civilian TECC will likely follow the military's lead, but it will lag by six to eighteen months as agencies sort out who is authorized to do what, and how to evidence the training.
That lag is going to create a real problem for civilian tactical medics. A SWAT medic running a long-extraction barricaded subject in a rural county is going to find themselves in scope-misalignment with the casualty's buddy who just took an updated TCCC course. The medic has the authority. The buddy does not. Or worse: the buddy thinks they do because they took a course, and the medic does not realize the buddy thinks so.
The fix is editorial. Medical directors need to read the 2026 guideline and the eventual TECC update side by side, and they need to put their conversion authorization in writing — by tier, by training requirement, by escalation pathway — before someone in their jurisdiction has the conversation they should have had in the conference room on a tarmac, in the middle of an extraction.
OTFC and IV Fentanyl are out! Suzetrigine is In
The 2026 analgesia rewrite is the change most likely to make a senior tac medic do a double take.
The 2024 Combat Wound Medication Pack centered on acetaminophen, meloxicam, and OTFC, with IV fentanyl as a parenteral option at the next tier. The 2026 CWMP drops OTFC and IV fentanyl from initial management.
The pack is now:
Acetaminophen 1000–1300 mg PO every 8 hours.
Meloxicam 15 mg PO once a day.
Suzetrigine 100 mg PO once (2 × 50 mg tablets), then 50 mg PO every 12 hours.
For casualties who cannot remain in the fight, TCCC medical personnel administer one of:
Ketamine 100 mg IM.
Ketamine 50 mg IN.
Ketamine 25 mg (or 0.2–0.3 mg/kg) IV or IO over 1 minute.
Esketamine 14 mg or 28 mg IN.
Repeat doses every 30 minutes as needed, targeting tolerable pain control while preserving airway, respiratory drive, and mentation.
The decision to pull OTFC and IV fentanyl was driven by logistics and accountability — controlled-substance handling under tactical conditions, chain-of-custody overhead, and the operational variability that comes with carrying a Schedule II analgesic to a place where it might or might not be needed. The clinical case for OTFC has always been strong. The operational case has always been complicated. CoTCCC made the call that operational reliability outweighed clinical optimization at the initial tier.
The addition of suzetrigine is the operationally significant move. Suzetrigine (brand name Journavx, approved by the FDA in January 2025) is a peripherally restricted Nav1.8 sodium channel blocker. In plain language: it blocks pain signal transmission at the level of the peripheral nerve, without crossing into the central nervous system in a way that produces euphoria, respiratory depression, or the cognitive blunting characteristic of opioids. The FDA approved it on the basis of two Phase 3 trials in acute post-surgical pain. It is not an opioid. It carries no abuse-deterrent labeling because it does not produce the reinforcement pattern that creates abuse risk.
For the tactical environment, that profile is close to ideal. A casualty taking suzetrigine retains airway control and respiratory drive, can communicate clearly, and can in many cases keep fighting. It does not carry the bleeding-risk concern that limits NSAID monotherapy in trauma. It is not a wonder drug — its efficacy in the acute post-surgical trials is moderate, not dramatic — but in a CWMP layered with acetaminophen and meloxicam, the analgesic ceiling moves up meaningfully without the opioid downside.
The ketamine simplification is welcome. The 2024 guideline carried four different IM/IN/IV dosing structures that almost nobody could recite under stress. The 2026 dosing — 100 mg IM, 50 mg IN, 25 mg or 0.2–0.3 mg/kg IV-IO — is something a medic can carry on a knee-board card. The addition of esketamine IN as a labeled alternative reflects the actual availability of esketamine intranasal formulations in NATO supply chains, and gives tac medics a more potent IN option for casualties who cannot tolerate IV access.
For civilian TECC, the analgesia changes are going to land harder than the military changes. Most civilian agencies built their tactical analgesia protocols around ketamine and fentanyl with no oral component beyond acetaminophen. The 2026 framework opens the door to a suzetrigine-anchored civilian tactical analgesia plan, but no civilian agency in the US has gone there yet, and most still have not approved esketamine for prehospital administration outside of psychiatric protocols.
Pediatric TCCC Arrives, Finally
For the first time in the program's history, the 2026 release includes a standalone pediatric TCCC document. That sentence should embarrass everyone who has worked tactical medicine in a school-shooting environment, hostage scenario involving juveniles, or active-shooter event at a community gathering with kids present. We have spent twenty years adapting adult protocols on the fly. The dosing was wrong. The communication assumptions were wrong. The post-trauma management for pediatric casualties has been a patchwork of pediatric ATLS, off-label PALS guidance, and operator improvisation.
The pediatric document addresses age-specific communication, weight-based dosing references, and post-incident management. It is not the last word on pediatric tactical care, but it is the first word from the body that owns tactical doctrine. For civilian TECC providers operating in school MCI scenarios, this is the document you should be reading next to your existing pediatric resuscitation references — not in place of them.
The Airway Split: TFC Says Surgical Cric. TECC Keep SGAs
The 2026 airway change is where the military-civilian divide is widest. In Tactical Field Care, the 2026 guideline names surgical cricothyroidotomy as the only invasive airway intervention. Supraglottic airways are out at TFC on the military side, with the rationale that field cric is faster, more reliable in disrupted anatomy from penetrating mechanism, and more durable through movement. The guideline also requires continuous EtCO2 in addition to SpO2. Pulse oximetry alone is no longer sufficient to verify ventilation in TFC.
Civilian TECC will not follow on the SGA decision. The mechanism mix in civilian tactical incidents is not the same as a battlefield blast scenario, and the medic-to-casualty ratio and provider tier distribution are different. Expect the next TECC update to retain SGAs in the civilian tactical airway algorithm and to mirror the EtCO2-plus-SpO2 monitoring requirement.
The clinical takeaway for civilian tactical medics is to be careful about translating the airway language verbatim from military TCCC to civilian protocol. The dosing changes translate cleanly. The airway algorithm does not.
TBI, Antibiotics, and Eye Trauma — Quieter Changes
The TBI section in TFC is tightened around three points: avoid hypoxia (target SpO2 at or above 92%), avoid hypotension (target systolic BP at or above 100 mmHg in adults), and avoid hypocapnia (target normocapnia with EtCO2 monitoring; treat herniation signs with brief, targeted hyperventilation, not routine hyperventilation). None of these are new concepts. The formal monitoring requirement is.
The antibiotic rewrite reflects the broader civilian trend away from fluoroquinolones in penetrating wound prophylaxis. Cefadroxil 1 g PO (preferred) or cephalexin 500 mg PO (alternative) replaces moxifloxacin for casualties who can take PO. Ceftriaxone 2 g IV/IO push over 3–5 minutes — reconstituted in normal saline only, not lactated Ringer's, because of calcium precipitation — replaces ertapenem for those who cannot. Flush IV/IO lines with 10–20 mL NS before and after administration. For IM administration, reconstitute with 4.2 mL NS or 1% lidocaine and inject into a large muscle (lateral thigh preferred).
The penetrating eye trauma refinement is incremental — improved language around protective shielding, avoidance of pressure dressings over the orbit, the importance of early ophthalmologic evaluation — but worth re-reading, because the 2024 language was ambiguous about scenarios where a casualty has both an orbital penetration and a coexisting head injury.
For Civilian Tactical Medics: What To Do This Month
The 2026 TCCC guideline is not a civilian document. TECC will publish an update over the coming months that translates the relevant pieces. While we wait for that document, civilian tactical medical directors should be doing five things right now:
Read the 2026 TCCC document. The official version is on the Joint Trauma System and mirrored in the Allogy library. It is not long.
Map your current TECC-aligned protocols against the 2026 changes. Mark the deltas. Most of them are clinically defensible to adopt now with medical director authorization.
Decide your conversion authority structure. Which tier of provider in your jurisdiction is authorized to perform tourniquet conversion? Under what conditions? With what training? Get it in writing now, not after an incident review.
Verify your tactical analgesia pack. Suzetrigine is FDA-approved but not yet on most civilian tactical formularies. Esketamine IN is approved for psychiatric use; off-label tactical use will require medical director sign-off and an evidenced protocol.
Update your pediatric tactical kit and your pediatric protocols against the new pediatric document. Confirm Broselow-equivalent weight estimation, pediatric airway adjuncts, and pediatric analgesia dosing references are current.
Bottom Line
The 2026 TCCC update is not a paint-the-edges revision. It is the formal end of the “apply and forget” tourniquet doctrine, the de-prioritization of opioid first-line analgesia in the field, the long-overdue arrival of pediatric tactical doctrine, and a tightening of monitoring requirements that demands more from every provider tier than the 2024 version did.
Tac medics who treat the first hour after wounding as the only hour will fail their patients under this guideline. The standard now is sustained, conditional, ongoing decision-making — reassessment, conversion, dose titration, monitoring. That is harder to teach, harder to practice, and harder to perform under stress than “apply and walk away.”
It is also, finally, what the evidence has been telling us to do for at least a decade.
Read the document. Read the pediatric annex. Pull your protocols. Have the medical director conversation. Update your CWMP loadout when the supply chain catches up. If you teach tactical medicine — and a lot of our readers do — rebuild your conversion module before your next class. Your students will be running calls under this guideline by Q4.
We will cover the TECC translation when it lands - BFEMS Out!
Sources
CoTCCC, Tactical Combat Casualty Care Guidelines, 1 May 2026, Joint Trauma System / Allogy.
JSOM, Standardizing Tourniquet Reassessment and Conversion Across TCCC Tiers: TCCC Proposed Change 25-2.
JSOM, Antibiotics in Tactical Combat Casualty Care 2025: TCCC Change 25-1.
European Journal of Trauma and Emergency Surgery: “Increasing prehospital tourniquet use attributed to non-indicated use: an 11-year retrospective study,” 2025.
Standifird et al., “Implementing Tourniquet Conversion Guidelines for Civilian EMS and Prehospital Organizations,” Wilderness & Environmental Medicine, 2024.
FDA Approval Letter for suzetrigine (Journavx), January 2025.
Wilderness Medical Society tourniquet conversion guidance.
This brief is editorial. It is not a protocol. Field practice should follow your medical director's written protocol and the most current TCCC / TECC guidelines available.
Comments